Your browser doesn't support javascript.
loading
A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma.
Gan, Leijuan; Lang, Mengran; Tian, Xindi; Ren, Shaohua; Li, Guangtao; Liu, Yayue; Han, Ruyu; Zhu, Kangwei; Li, Huikai; Wu, Qiang; Cui, Yunlong; Zhang, Wei; Fang, Feng; Li, Qiang; Song, Tianqiang.
Afiliación
  • Gan L; Department of Hepatobiliary Cancer, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of China.
  • Lang M; Key Laboratory of Cancer Prevention and Therapy, Tianjin, People's Republic of China.
  • Tian X; Tianjin's Clinical Research Center for Cancer, Tianjin, People's Republic of China.
  • Ren S; Department of Hepatobiliary Cancer, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of China.
  • Li G; Key Laboratory of Cancer Prevention and Therapy, Tianjin, People's Republic of China.
  • Liu Y; Tianjin's Clinical Research Center for Cancer, Tianjin, People's Republic of China.
  • Han R; Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Hebei Cancer Hospital, Chinese Academy of Medical Sciences, Langfang, Hebei, 065001, People's Republic of China.
  • Zhu K; Department of Hepatobiliary Cancer, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of China.
  • Li H; Key Laboratory of Cancer Prevention and Therapy, Tianjin, People's Republic of China.
  • Wu Q; Tianjin's Clinical Research Center for Cancer, Tianjin, People's Republic of China.
  • Cui Y; Department of Hepatobiliary Cancer, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of China.
  • Zhang W; Key Laboratory of Cancer Prevention and Therapy, Tianjin, People's Republic of China.
  • Fang F; Tianjin's Clinical Research Center for Cancer, Tianjin, People's Republic of China.
  • Li Q; Department of Hepatobiliary Cancer, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, People's Republic of China.
  • Song T; Key Laboratory of Cancer Prevention and Therapy, Tianjin, People's Republic of China.
J Hepatocell Carcinoma ; 10: 673-686, 2023.
Article en En | MEDLINE | ID: mdl-37125392
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Hepatocell Carcinoma Año: 2023 Tipo del documento: Article Pais de publicación: Nueva Zelanda
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Hepatocell Carcinoma Año: 2023 Tipo del documento: Article Pais de publicación: Nueva Zelanda